Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma

Profound intratumoral genomic heterogeneity has limited the ability of targeted therapies to overcome therapy resistance in glioblastoma. We have defined purine metabolism as a key mediator of DNA repair and radiation resistance in glioblastoma. Because many glioblastoma oncogenic drivers activate p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Weihua, Wahl, Daniel R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671052/
https://www.ncbi.nlm.nih.gov/pubmed/33235923
http://dx.doi.org/10.1080/23723556.2020.1834902
Descripción
Sumario:Profound intratumoral genomic heterogeneity has limited the ability of targeted therapies to overcome therapy resistance in glioblastoma. We have defined purine metabolism as a key mediator of DNA repair and radiation resistance in glioblastoma. Because many glioblastoma oncogenic drivers activate purine metabolism, its inhibition may overcome therapy resistance despite intratumoral genomic heterogeneity.

Ejemplares similares